1. Home
  2. FC vs ALLO Comparison

FC vs ALLO Comparison

Compare FC & ALLO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • FC
  • ALLO
  • Stock Information
  • Founded
  • FC 1983
  • ALLO 2017
  • Country
  • FC United States
  • ALLO United States
  • Employees
  • FC N/A
  • ALLO N/A
  • Industry
  • FC Other Consumer Services
  • ALLO Biotechnology: Biological Products (No Diagnostic Substances)
  • Sector
  • FC Consumer Discretionary
  • ALLO Health Care
  • Exchange
  • FC Nasdaq
  • ALLO Nasdaq
  • Market Cap
  • FC 239.1M
  • ALLO 231.9M
  • IPO Year
  • FC 1992
  • ALLO 2018
  • Fundamental
  • Price
  • FC $19.10
  • ALLO $1.13
  • Analyst Decision
  • FC Strong Buy
  • ALLO Strong Buy
  • Analyst Count
  • FC 2
  • ALLO 10
  • Target Price
  • FC $27.00
  • ALLO $8.88
  • AVG Volume (30 Days)
  • FC 149.0K
  • ALLO 4.0M
  • Earning Date
  • FC 11-05-2025
  • ALLO 11-06-2025
  • Dividend Yield
  • FC N/A
  • ALLO N/A
  • EPS Growth
  • FC N/A
  • ALLO N/A
  • EPS
  • FC 0.81
  • ALLO N/A
  • Revenue
  • FC $279,943,000.00
  • ALLO N/A
  • Revenue This Year
  • FC N/A
  • ALLO N/A
  • Revenue Next Year
  • FC $1.23
  • ALLO $100.00
  • P/E Ratio
  • FC $23.77
  • ALLO N/A
  • Revenue Growth
  • FC N/A
  • ALLO N/A
  • 52 Week Low
  • FC $18.32
  • ALLO $0.86
  • 52 Week High
  • FC $44.16
  • ALLO $3.78
  • Technical
  • Relative Strength Index (RSI)
  • FC 45.07
  • ALLO 47.72
  • Support Level
  • FC $18.69
  • ALLO $1.06
  • Resistance Level
  • FC $19.67
  • ALLO $1.18
  • Average True Range (ATR)
  • FC 0.68
  • ALLO 0.08
  • MACD
  • FC 0.03
  • ALLO 0.01
  • Stochastic Oscillator
  • FC 28.48
  • ALLO 41.83

About FC Franklin Covey Company

Franklin Covey Co is a company focused on organizational performance improvement. It focuses on providing time management and effectiveness training for individuals and corporations via online training as well as in-person workshops and events. The company provides training and consulting services in the areas of leadership, execution, productivity, trust, sales performance, customer loyalty, and educational improvement. It operates in the business segments of Direct Offices, Education division, and International Licensees. The company derives revenue from providing training and consulting services, and through the selling of books, audio media, and other related products. It has a business presence in the Australia, New Zealand, China, Japan, United Kingdom, Ireland, and Other countries.

About ALLO Allogene Therapeutics Inc.

Allogene Therapeutics Inc is a clinical-stage biotech firm specializing in immuno-oncology, focusing on the development of genetically engineered allogeneic T-cell products for cancer and autoimmune diseases. Their pipeline includes off-the-shelf T-cell candidates designed to target cancer cells or autoreactive cells in autoimmune disorders. Notably, their allogeneic approach, derived from healthy donors, allows for broader patient eligibility and scalability. With a vision to redefine CAR T therapy, the company concentrates on core programs targeting lymphoma, leukemia, autoimmune diseases, and solid tumors. Revenue, generated from collaborations and licensing agreements, supports their research and development efforts.

Share on Social Networks: